Full Disclosure
April 9, 2019
Oncologists frequently receive “gifts” from pharma companies, but how much is too much?
0 min read
March 2019
Welcome to the March issue! How much is a medicine worth? What about a human life? These questions are the focus of this month’s cover feature on cell and gene therapies. Meanwhile in Upfront, researchers develop a new AI platform that aims to harness scientific data for improved drug development, and we ask whether financial relationships between oncologists and pharma affect clinical practice in inappropriate ways. In Business, Peter Beavis argues that too many companies are missing out on crucial R&D tax credits; and Angela Osborne reveals how she created her own space in the cell and gene therapy industry, in Profession. We also Sit Down With Dave Tudor, who is working on “grand challenges” at the Medicines Manufacturing Innovation Centre, Scotland, UK.
Soak it Up!
April 9, 2019
A polymer-coated device could help minimize the side effects of chemotherapy
0 min read
Discovery & Development
Drug Discovery
Research News
Facilities & Equipment
Technology & Manufacturing
Connecting the Data
April 9, 2019
A new AI platform aims to harness scientific data for improved drug development
0 min read
Scottish Pride and Innovation
April 9, 2019
Sitting Down With… Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), Scotland, UK.
0 min read
So Long and Thanks for all the Drugs
April 2, 2019
Scott Gottlieb prepares to leave the FDA after accomplishing much.
0 min read
Let's Meet in the Middle
April 2, 2019
As long as payers recognize the value of a curative treatment and manufacturers are flexible with payment plans, patients will have access to cell and gene therapies.
0 min read
Tax Credits: Your Work is Worth it
April 2, 2019
Research and development tax reliefs are available for businesses in many countries, but some companies consider the area to be too complex and daunting and, in some cases, are too humble about their innovative projects.
0 min read
Advanced Therapies: The Price is Right?
March 25, 2019
Health technology assessments find that many cell and gene therapies are more cost effective than existing treatments and managing symptoms with palliative care. But are healthcare systems and manufacturers ready to embrace evidence-based pricing to lessen the impact of upfront costs?
0 min read
Building a Business: Lessons Learned with Angela Osborne
March 25, 2019
Not allowing herself to be defined by stereotypes, Angela Osborne has created her own space in the industry and is helping the cell and gene therapy industry to bloom. Here, she shares the pivotal moments leading to the creation of the consultancy, eXmoor Pharma.
0 min read
It’s Complicated
March 22, 2019
The potential market for complex generics is substantial, but navigating the FDA’s guidance for proving “sameness” is a real minefield...
0 min read
NextGen Now: Delivering Tomorrow's Facilities Today
March 22, 2019
If cell and gene therapy products are to successfully reach patients and deliver transformative cures, then the industry will need more facilities capable of manufacturing them.
0 min read
A Step Change in Pharmaceutical Glass Packaging Innovation
March 22, 2019
Corning’s analysis into the root cause of glass delamination-related recalls identified boron as the culprit, explaining why process control of borosilicate vials only reduce the risk. As a result, Corning glass scientists developed Valor® Glass, a revolutionary, new aluminosilicate glass composition, developed specifically for pharmaceutical use to eliminate delamination.
0 min read
The Upstream/Downstream Process Balancing Act
March 22, 2019
Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.
0 min read
The Color of Chirality
March 19, 2019
Forty years ago, it was theorized that chirality had a color composition that could be measured… and finally the theory has been proven.
0 min read
Perusing the Pipeline
March 19, 2019
With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe – from preclinical studies through to phase III trials.
0 min read
C&G Therapy? That’ll Do NICEly
March 19, 2019
The striking combination of remarkable, long-lasting, clinical effectiveness and a hefty price tag presents a real challenge to health technology assessors considering cell and gene therapies. Nick Crabb explains how the UK’s health technology assessment agency, NICE, is tackling the problem.
0 min read
Animal-Free; Risk-Free
March 18, 2019
If you or your supplier are working with animal-derived components then you run the risk of exposing patients to dangerous contaminations.
0 min read
RePURPOSED
February 13, 2019
Recycled and reused: scientists develop a library to help teach old drugs new tricks.
0 min read
